Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies — the Polish experience

Czarnowska, Agata; Brola, Waldemar; Zajkowska, Olga; Rusek, Stanislaw; Adamczyk-Sowa, Monika; Kubicka-Bączyk, Katarzyna; Kalinowska-Łyszczarz, Alicja; Kania, Karolina; Słowik, Agnieszka; Wnuk, Marcin; Marona, Monika; Podlecka-Piętowska, Aleksandra; Nojszewska, Monika; Zakrzewska-Pniewska, Beata; Jasińska, Elżbieta; Gołuch, Katarzyna; Lech, B; Noga, Magdalena; Perenc, Lidia; Popiel, Małgorzata; Lasek–Bal, Anetta; Puz, Przemysław; Maciejowska, Katarzyna; Kucharska-Lipowska, Marta; Lipowski, Michał; Kapica-Topczewska, Katarzyna; Chorąży, Monika; Tarasiuk, Joanna; Kochanowicz, Jan; Kulikowska, Joanna; Wawrzyniak, Sławomir; Niezgodzińska-Maciejek, Anna; Pokryszko−Dragan, Anna; Gruszka, Ewa; Budrewićz, Sławomir; Białek, Marta; Kurkowska‐Jastrzębska, Iwona; Kurowska, Katarzyna; Stępień, Adam; Włodek, Agata; Ptasznik, Violetta; Pawełczyk, Małgorzata; Sobolewski, Piotr; Lejmel, Henryka; Strzalińska, Katarzyna; Maciejowski, Maciej; Tutaj, Andrzej; Zwiernik, Jacek; Litwin, Anna; Lewańczyk, Bożena; Paprocka, Izabela; Zwiernik, Beata; Pawlos, Aleksandra; Borysowicz, Andrzej; Narożnik, Anna; Michałowska, Anna; Nosek, Krzysztof; Fudala, Małgorzata; Milewska-Jędrzejczak, Marta; Kułakowska, Alina; Bartosik-Psujek, Halina

doi:10.5603/pjnns.a2021.0031

Cited by 30 publications

(34 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Numerous recent publications (including our recent publication concerning patients with MS) conclude that the course of SARS-CoV-2 infection in individuals with MS is generally favorable [6,19,20]. There is no proof that most DMTs have a negative impact on the course of the diseases.…”

Section: Discussionmentioning

confidence: 99%

“…There has been much uncertainty about the course of the disease in individuals undergoing disease modifying therapies (DMTs). The initial studies do not suggest an unfavorable course [5,6]. Several point out a greater risk of severe infection in people treated with anti-CD20 agents, but there are significant limitations (small number of cohorts) to draw any final conclusions.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland

Czarnowska

Kapica-Topczewska

Zajkowska

et al. 2021

JCM

Self Cite

View full text Add to dashboard Cite

(1) Background: To report and analyze the presence of residual symptoms after SARS-CoV-2 infection among Polish patients with multiple sclerosis (MS) treated with different disease-modifying therapies (DMTs). (2) Methods: The study included 426 individuals with MS treated with DMTs and confirmed SARS-CoV-2 infection from 12 Polish MS centers. The data were collected through to 31 May 2021. The information included demographics, specific MS characteristics, course of SARS-CoV-2 infection, and residual (general and neurological) symptoms lasting more than four and 12 weeks after the initial infection. The results were obtained using maximum likelihood estimates for odds ratio and logistic regression. (3) Results: A total of 44.84% patients with MS reported symptoms lasting between four and 12 weeks after the initial infection; 24.41% people had symptoms that resolved up to 12 weeks, and 20.42% patients had symptoms that lasted over 12 weeks. The most common symptoms were: fatigue, disturbance of concentration, attention, and memory, cognitive complaints, and headache. None of the DMTs were predisposed to the development of residual symptoms after the initial infection. A total of 11.97% of patients had relapse three months prior or after SARS-CoV-2 infection. (4) Conclusion: Almost half of individuals with MS treated with different DMTs had residual symptoms after SARS-CoV-2 infection. None of the DMTs raised the probability of developing post-acute COVID symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland

Czarnowska

Kapica-Topczewska

Zajkowska

et al. 2021

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…Various studies did not find any association between the degree of disability in MS cases and risk of severe COVID-19 ( Alonso et al, 2021 ; Czarnowska et al, 2021 ; Sen et al, 2021 ), while other scientists highlight the possible relation ( Klineova et al, 2021 ; Louapre et al, 2020 ; Sormani et al, 2021a ). Our results are in line with the latter.…”

Section: Discussionmentioning

confidence: 99%

The study of COVID-19 infection following vaccination in patients with multiple sclerosis

Ghadiri

Sahraian

Azimi

et al. 2022

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

“…In einer polnischen Kohorte wurden 396 MS-Erkrankte, die unter Behandlung mit Immuntherapien eine COVID-19-Erkrankung erlitten hatten, untersucht [ 26 ]. Das mediane Alter war 39 Jahre, der mediane EDSS war 2 und die mittlere Krankheitsdauer 9 Jahre.…”

Section: Sars-cov-2-infektion Unter Behandlung Mit Cladribin-tablettenunclassified

“…Fälle von COVID-19 unter Cladribin-Tabletten, in denen auch die humorale Immunantwort bestimmt wurde, werden im nachfolgenden Kapitel besprochen. In einer polnischen Kohorte wurden 396 MS-Erkrankte, die unter Behandlung mit Immuntherapien eine COVID-19-Erkrankung erlitten hatten, untersucht [26]. Das mediane Alter war 39 Jahre, der mediane EDSS war 2 und die mittlere Krankheitsdauer 9 Jahre.…”

Section: Sars-cov-2-infektion Unter Behandlung Mit Cladribin-tablettenunclassified

Einblicke in die Behandlung der Multiplen Sklerose mit Cladribin-Tabletten seit Beginn der COVID-19-Pandemie

Sellner

2021

psychopraxis. neuropraxis

View full text Add to dashboard Cite

Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies — the Polish experience

Abstract: 213 www.journals.viamedica.pl/neurologia_neurochirurgia_polska Agata Czarnowska et al., SARS-CoV-2 infection in MS patients treated with disease-modifying therapies

Cited by 30 publications

References 42 publications

Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland

Symptoms after COVID-19 Infection in Individuals with Multiple Sclerosis in Poland

The study of COVID-19 infection following vaccination in patients with multiple sclerosis

Einblicke in die Behandlung der Multiplen Sklerose mit Cladribin-Tabletten seit Beginn der COVID-19-Pandemie

Contact Info

Product

Resources

About